中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
11期
1968-1969
,共2页
脂联素%C反应蛋白%脑梗死%疏血通%阿魏酸钠
脂聯素%C反應蛋白%腦梗死%疏血通%阿魏痠鈉
지련소%C반응단백%뇌경사%소혈통%아위산납
APN%C-Reactive Protein%Brain infarction%Shuxuetong%Sodium ferulate
目的 观察脂联素(APN)和超敏C反应蛋白(HsCRP)水平的变化,对急性脑梗死患者治疗的影响.方法 选择64例急性脑梗死患者,随机分为治疗组32例、对照组32例,治疗组采用疏血通联合阿魏酸钠治疗,对照组采用胞二磷胆碱治疗.对脑梗死患者分别在治疗前后进行脂联素(APN)和超敏C反应蛋白(HsCRP)水平的检测.结果 两组患者治疗前后脂联素(APN)和超敏C反应蛋白(HsCRP)水平差异有统计学意义(P＜0.01,P＜0.05),且两组治疗后差异均有统计学意义(P＜0.05).结论 脂联素和超敏C反应蛋白能反映急性脑梗死病情变化.
目的 觀察脂聯素(APN)和超敏C反應蛋白(HsCRP)水平的變化,對急性腦梗死患者治療的影響.方法 選擇64例急性腦梗死患者,隨機分為治療組32例、對照組32例,治療組採用疏血通聯閤阿魏痠鈉治療,對照組採用胞二燐膽堿治療.對腦梗死患者分彆在治療前後進行脂聯素(APN)和超敏C反應蛋白(HsCRP)水平的檢測.結果 兩組患者治療前後脂聯素(APN)和超敏C反應蛋白(HsCRP)水平差異有統計學意義(P＜0.01,P＜0.05),且兩組治療後差異均有統計學意義(P＜0.05).結論 脂聯素和超敏C反應蛋白能反映急性腦梗死病情變化.
목적 관찰지련소(APN)화초민C반응단백(HsCRP)수평적변화,대급성뇌경사환자치료적영향.방법 선택64례급성뇌경사환자,수궤분위치료조32례、대조조32례,치료조채용소혈통연합아위산납치료,대조조채용포이린담감치료.대뇌경사환자분별재치료전후진행지련소(APN)화초민C반응단백(HsCRP)수평적검측.결과 량조환자치료전후지련소(APN)화초민C반응단백(HsCRP)수평차이유통계학의의(P＜0.01,P＜0.05),차량조치료후차이균유통계학의의(P＜0.05).결론 지련소화초민C반응단백능반영급성뇌경사병정변화.
Objective To investigate the changes of APN and HsCRP levels in patients with cerebral infarction and to observe whether treated with shuxuetong plus sodium ferulate improves the APN and HsCRP levels of patients with cerebral infarction.Methods All patients were randomly divided into treated group and control group.Patients in treated group were treated with shuxuetong and sodium ferulate.Patients in control group were treated with Citicoline.Plasma APN and HsCRP levels were measured in all patients before and after treatent.Results The levels of plasma APN and HsCRP in the two groups before and after treatment were significantly different respectively(P＜0.01,P＜0.05).After treated,the levels of plasma APN and HsCRP in treated group wee better than those in control group(P＜0.05).Conclusion Shuxuetong plus sodium ferulate can effectively improve plasma APN and HsCRP levels of cerebral infarction.
